Bayer to Collaborate With CureVac on Covid-19 Vaccine Candidate
January 07 2021 - 3:15AM
Dow Jones News
By Giulia Petroni
Bayer AG said Thursday that it has agreed to collaborate with
CureVac NV to support the development and supply of the U.S.-listed
biopharmaceutical company's Covid-19 vaccine candidate CVnCoV.
Under the agreement, the German chemical and pharmaceutical
conglomerate will support CureVac with country operations within
the European Union and selected additional markets in order to
facilitate the supply of several hundred million doses. CureVac
will be the marketing authorization holder for the product.
The financial terms of the deal weren't disclosed.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
January 07, 2021 03:00 ET (08:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Sep 2023 to Sep 2024